Amedeo Smart

Free Medical Literature Service

 

Amedeo

Autoimmune Disorders
  Free Subscription

Articles published in
Kidney Int
    October 2025
  1. FLOEGE J, Barratt J, Cook HT, Noronha IL, et al
    Executive summary of the KDIGO 2025 Clinical Practice Guideline for the Management of Immunoglobulin A Nephropathy (IgAN) and Immunoglobulin A Vasculitis (IgAV).
    Kidney Int. 2025;108:548-554.
    >> Share

  2. THEIS JD, Nasr SH, Sethi S
    Absence of PCDH7-associated dual antigens in membranous nephropathy.
    Kidney Int. 2025;108:707-708.
    >> Share

    September 2025
  3. FU R, Wang W, Huo Y, Li L, et al
    Corrigendum to "The mechanosensitive ion channel Piezo1 contributes to podocyte cytoskeleton remodeling and development of proteinuria in lupus nephritis." Kidney International 2024;106:625-639.
    Kidney Int. 2025;108:511-512.
    >> Share

  4. GHASEMI M, Weins A
    Distinguishing signal from noise: a new era of autoantibody testing in podocytopathies requires thoughtful approaches.
    Kidney Int. 2025;108:349-351.
    >> Share

    August 2025
  5. REESE PP, Mohan S, Schaubel DE, Forbes R, et al
    Low prevalence of glomerulonephritis in transplanted kidneys from deceased donors with active hepatitis C virus infection.
    Kidney Int. 2025 Aug 22:S0085-2538(25)00657-X. doi: 10.1016/j.kint.2025.
    >> Share

  6. CHAN EY, Marks SD
    Childhood-onset lupus nephritis: unique aspects and challenges in management.
    Kidney Int. 2025 Aug 20:S0085-2538(25)00645-3. doi: 10.1016/j.kint.2025.
    >> Share

  7. AL-RABADI LF, Beck LH Jr
    The podocyte gets a pedicure: tiny nail clippers for podocyte foot processes.
    Kidney Int. 2025;108:176-178.
    >> Share

  8. SONG ZR, Liu ZY, Li MS, Li Y, et al
    Expanding the spectrum of genetic causes of DNA-specific exonuclease TREX1 variants in thrombotic microangiopathy.
    Kidney Int. 2025;108:317-320.
    >> Share

  9. ROSENBAUM D, Reichelt J, Gudaitis S, Kuhne S, et al
    Regulation of podocyte surface proteins by the enzyme A Disintegrin And Metalloproteinase 10 (ADAM10).
    Kidney Int. 2025;108:214-232.
    >> Share

    July 2025
  10. HEERINGA P, Rutgers A
    Triggering trouble: post-translational modifications may drive myeloperoxidase autoimmunity.
    Kidney Int. 2025 Jul 14:S0085-2538(25)00480-6. doi: 10.1016/j.kint.2025.
    >> Share

  11. HOU W, Yao Y, Dun D, Xia Y, et al
    Q fever endocarditis and glomerulonephritis.
    Kidney Int. 2025;108:156.
    >> Share

    June 2025
  12. MASOUD S, Wong K, Pitcher D, Downward L, et al
    Quantifying association of early proteinuria and estimated glomerular filtration rate changes with long-term kidney failure in C3 glomerulopathy and immune-complex membranous proliferative glomerulonephritis using the United Kingdom RaDaR Registry.
    Kidney Int. 2025 Jun 27:S0085-2538(25)00491-0. doi: 10.1016/j.kint.2025.
    >> Share

  13. FLOEGE J, Lafayette R, Barratt J, Schwartz B, et al
    Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Assessing the Efficacy and Safety of Felzartamab for IgA Nephropathy.
    Kidney Int. 2025 Jun 26:S0085-2538(25)00488-0. doi: 10.1016/j.kint.2025.
    >> Share

  14. CAZA TN, Arivett BA, Hassen SI, Al-Rabadi LF, et al
    Detection and Characterization of NELL1 Autoantibodies in NELL1 Positive Membranous Nephropathy.
    Kidney Int. 2025 Jun 18:S0085-2538(25)00481-8. doi: 10.1016/j.kint.2025.
    >> Share

  15. LIU P, Liu S, Dalal V, Lane J, et al
    Evaluation of Methodologies in Anti-nephrin Autoantibody Detection.
    Kidney Int. 2025 Jun 7:S0085-2538(25)00430-2. doi: 10.1016/j.kint.2025.
    >> Share

  16. ZAND L, Russo I, Vargas-Brochero MJ, Nasr SH, et al
    Phospholipase A2receptor-positive membranous nephropathy detected by laser microdissection and mass spectrometry in patients negative by immunofluorescence for phospholipase A2receptor on kidney biopsy.
    Kidney Int. 2025 Jun 6:S0085-2538(25)00428-4. doi: 10.1016/j.kint.2025.
    >> Share

    May 2025
  17. KOOIENGA L, Lee EY, Kim SG, Thomas H, et al
    Zigakibart demonstrates clinical safety and efficacy in a Phase 1/2 trial of healthy volunteers and patients with IgA nephropathy.
    Kidney Int. 2025 May 30:S0085-2538(25)00414-4. doi: 10.1016/j.kint.2025.
    >> Share

  18. HANNA C, Basiaga ML, Kastl JT, Caza TN, et al
    PCSK6-associated membranous nephropathy in an adolescent with Sjogren disease.
    Kidney Int. 2025;107:940-942.
    >> Share

  19. BELMONT HM
    Lupus nephritis treat to target normalizing anti-dsDNA, C3, and C4 is a bridge too far.
    Kidney Int. 2025;107:937.
    >> Share

  20. BENYAHIA R, Gueye S, Colombat M, Chauveau D, et al
    Glomerular deposits of neuron-derived neurotrophic factor in a case of membranous nephropathy lacking syphilis signature.
    Kidney Int. 2025;107:935-936.
    >> Share

    April 2025
  21. OSTENDORF L, Rao DA
    ILC1s drive tissue-aggressive macrophages in experimental lupus nephritis.
    Kidney Int. 2025 Apr 28:S0085-2538(25)00262-5. doi: 10.1016/j.kint.2025.
    >> Share

  22. PAWLUCZYK IZ, Bhachu JS, Brown JR, Lacey M, et al
    B cell-derived exosomal miR-483-5p and its potential role in promoting kidney function loss in IgA nephropathy.
    Kidney Int. 2025 Apr 21:S0085-2538(25)00324-2. doi: 10.1016/j.kint.2025.
    >> Share

  23. JERKE U, Eulenberg-Gustavus C, Wagner DL, Schreiber A, et al
    CRISPR-Cas9 mediated proteinase 3 autoantigen deletion as a treatment strategy for anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
    Kidney Int. 2025 Apr 21:S0085-2538(25)00325-4. doi: 10.1016/j.kint.2025.
    >> Share

  24. EGGENHUIZEN PJ, Ng BH, Lo C, Chang J, et al
    Engineered antigen-specific T regulatory cells suppress autoreactivity to the anti-glomerular basement membrane disease antigen.
    Kidney Int. 2025;107:751-756.
    >> Share

  25. SHIRAI Y, Miura K, Morimoto K, Yokoo T, et al
    Reevaluating anti-nephrin autoantibodies by ELISA using human embryonic kidney-derived recombinant extracellular domain of human nephrin.
    Kidney Int. 2025;107:757-759.
    >> Share

    March 2025
  26. ROUSSELLE A, Lodka D, Sonnemann J, Kling L, et al
    Endothelial but not systemic ferroptosis inhibition protects from antineutrophil cytoplasmic antibody-induced crescentic glomerulonephritis.
    Kidney Int. 2025 Mar 21:S0085-2538(25)00250-9. doi: 10.1016/j.kint.2025.
    >> Share

  27. ODLER B, Riedl R, Geetha D, Szpirt WM, et al
    The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial.
    Kidney Int. 2025;107:558-567.
    >> Share

  28. SHAH SI, Paudel S, Dalland JC, McPhail EM, et al
    Concurrent AL amyloidosis and fibrillary glomerulonephritis.
    Kidney Int. 2025;107:579.
    >> Share

    February 2025
  29. HENGEL FE, Dehde S, Yilmaz A, Bayazit AK, et al
    Anti-nephrin autoantibodies in steroid-resistant nephrotic syndrome may inform treatment strategy.
    Kidney Int. 2025 Feb 6:S0085-2538(25)00082-1. doi: 10.1016/j.kint.2025.
    >> Share

    January 2025
  30. FLOEGE J, Bernier-Jean A, Barratt J, Rovin B, et al
    Treatment of Patients with IgA Nephropathy: A call for a new paradigm.
    Kidney Int. 2025 Jan 31:S0085-2538(25)00076-6. doi: 10.1016/j.kint.2025.
    >> Share

  31. PRUNOTTO M, Nachman PH, Gillespie BS, Beck LH Jr, et al
    Designing clinical trials for the treatment of membranous nephropathy in the anti-PLA2R era: results of a Nephcure membranous nephropathy workshop.
    Kidney Int. 2025 Jan 28:S0085-2538(24)00776-2. doi: 10.1016/j.kint.2024.
    >> Share

  32. CANNEY M, Atiquzzaman M, Zheng Y, Induruwage D, et al
    Evaluating the risk of cardiovascular events associated with different immunosuppression treatments for glomerular diseases.
    Kidney Int. 2025;107:143-154.
    >> Share

    December 2024
  33. CHENG C, Li B, Li J, Wang Y, et al
    Multi-stain deep learning prediction model of treatment response in lupus nephritis based on renal histopathology.
    Kidney Int. 2024 Dec 27:S0085-2538(24)00923-2. doi: 10.1016/j.kint.2024.
    >> Share

  34. FOLESTAD E, Mehlem A, Ning FC, Oosterveld T, et al
    Vascular endothelial growth factor B-mediated fatty acid flux in the adipose-kidney axis contributes to lipotoxicity in diabetic kidney disease.
    Kidney Int. 2024 Dec 15:S0085-2538(24)00872-X. doi: 10.1016/j.kint.2024.
    >> Share

    November 2024
  35. AL-AUBODAH TA, Piccirillo CA, Trachtman H, Takano T, et al
    The autoimmune architecture of childhood idiopathic nephrotic syndrome.
    Kidney Int. 2024 Nov 19:S0085-2538(24)00804-4. doi: 10.1016/j.kint.2024.
    >> Share

  36. KASINATH V, Tsokos GC
    PI3Kalpha in the pathogenesis and treatment of lupus nephritis.
    Kidney Int. 2024 Nov 16:S0085-2538(24)00794-4. doi: 10.1016/j.kint.2024.
    >> Share

  37. DE VRIESE AS, Sethi S, Fervenza FC
    Lupus Nephritis: Redefining the treatment goals.
    Kidney Int. 2024 Nov 7:S0085-2538(24)00781-6. doi: 10.1016/j.kint.2024.
    >> Share

  38. LARKINS NG, Craig JC
    Using prediction models to improve care and communicate risk: updated modeling for children with IgA nephropathy.
    Kidney Int. 2024;106:790-792.
    >> Share

  39. HU P, Xiao H, Alba MA, Atkins HM, et al
    Myeloperoxidase-ANCA IgG induces different forms of small vessel vasculitis based on type of synergistic immune stimuli.
    Kidney Int. 2024;106:870-886.
    >> Share

  40. CHEUNG CK, Barratt J, Lafayette R, Liew A, et al
    Targeting APRIL in the treatment of glomerular diseases.
    Kidney Int. 2024;106:806-818.
    >> Share

    October 2024
  41. MACHALITZA M, Debiec H, Krumpelmann B, Ferru N, et al
    PCDH7-antibodies and PCDH7 immune deposits are mostly found in patients with PLA(2)R1- or NELL1-associated membranous nephropathy.
    Kidney Int. 2024 Oct 24:S0085-2538(24)00725-7. doi: 10.1016/j.kint.2024.
    >> Share

  42. VODEHNAL S, Mohan C
    Urinary biomarkers for active Lupus Nephritis that have survived independent validation across cohorts.
    Kidney Int. 2024 Oct 4:S0085-2538(24)00696-3. doi: 10.1016/j.kint.2024.
    >> Share

  43. ROSALES IA, Zhou IY, Ay I, Sojoodi M, et al
    Imaging kidney inflammation using an oxidatively activated MRI probe.
    Kidney Int. 2024;106:671-678.
    >> Share

  44. HATTORI M
    Anti-nephrin autoantibodies: novel predictors of post-transplant recurrence of focal segmental glomerular sclerosis.
    Kidney Int. 2024;106:570-572.
    >> Share

    September 2024
  45. CHEN Z, Li X, Li C, Cai J, et al
    The significance of subclassifying focal segmental glomerulosclerosis lesions (S1) in IgA nephropathy.
    Kidney Int. 2024;106:540.
    >> Share

    August 2024
  46. SELVASKANDAN H, Barratt J
    The mucosal microbiome and IgA nephropathy: a new target for treatment?
    Kidney Int. 2024 Aug 29:S0085-2538(24)00621-5. doi: 10.1016/j.kint.2024.
    >> Share

  47. VRANA JA, Theis JD, Wegwerth PJ, Dasari S, et al
    A reliable clinical test for detection of membranous nephropathy antigens using laser microdissection and mass spectrometry.
    Kidney Int. 2024 Aug 26:S0085-2538(24)00618-5. doi: 10.1016/j.kint.2024.
    >> Share

  48. SETHI S, Madden B, Moura MC, Nasr SH, et al
    FAT1 is a target antigen in a subset of de novo allograft membranous nephropathy associated with antibody mediated rejection.
    Kidney Int. 2024 Aug 22:S0085-2538(24)00569-6. doi: 10.1016/j.kint.2024.
    >> Share

    July 2024
  49. BARBOUR SJ, Coppo R, Er L, Russo ML, et al
    Application of the updated International IgA Nephropathy Prediction Tool in children one- or two-years post-biopsy.
    Kidney Int. 2024 Jul 31:S0085-2538(24)00532-5. doi: 10.1016/j.kint.2024.
    >> Share

  50. FU R, Wang W, Huo Y, Li L, et al
    The mechanosensitive ion channel Piezo1 contributes to podocyte cytoskeleton remodeling and development of proteinuria in lupus nephritis.
    Kidney Int. 2024 Jul 29:S0085-2538(24)00529-5. doi: 10.1016/j.kint.2024.
    >> Share

  51. CHOU YL, Chen HL, Hsu BG, Yang CY, et al
    Galectin-3 contributes to pathogenesis of IgA nephropathy.
    Kidney Int. 2024 Jul 29:S0085-2538(24)00527-1. doi: 10.1016/j.kint.2024.
    >> Share

    June 2024
  52. TANG J, Xiao Z, Liu L, Li X, et al
    Renal artery microaneurysms in antineutrophil cytoplasmic antibody-associated vasculitis.
    Kidney Int. 2024;105:1326.
    >> Share

  53. ROVIRA J, Arana C, Garcia-Busquets A, Gille I, et al
    Chimeric autoantibody receptor cell therapy for the treatment of membranous nephropathy.
    Kidney Int. 2024;105:1320.
    >> Share

  54. HAAS M
    Podocyte injury as a potential therapeutic target in IgA nephropathy: should pathology guide us?
    Kidney Int. 2024;105:1165-1167.
    >> Share

  55. UEDA Y, Nakazawa D, Nishio S, Shiratori-Aso S, et al
    Transcription factor Nrf2 activation regulates NETosis, endothelial injury, and kidney disease in myeloperoxidase-positive antineutrophil cytoplasmic antibody-associated vasculitis.
    Kidney Int. 2024;105:1291-1305.
    >> Share

    May 2024
  56. ABBAD L, Detrait M, Kavvadas P, Bergonnier D, et al
    Signaling through cAMP-Epac1 induces metabolic reprogramming to protect podocytes in glomerulonephritis.
    Kidney Int. 2024 May 29:S0085-2538(24)00380-6. doi: 10.1016/j.kint.2024.
    >> Share

    April 2024
  57. NARAYANAN R, Sivadas S, Kurien AA
    NELL-1 associated membranous nephropathy linked to skin fairness cream use- insights from an Indian case series.
    Kidney Int. 2024 Apr 12:S0085-2538(24)00263-1. doi: 10.1016/j.kint.2024.
    >> Share

  58. SELVASKANDAN H, Barratt J
    Charting new frontiers in IgA nephropathy: a paradigm shift toward precision medicine and early intervention?
    Kidney Int. 2024;105:659-661.
    >> Share

    March 2024
  59. BELLUR SS, Troyanov S, Vorobyeva O, Coppo R, et al
    Evidence from the large VALIGA cohort validates the subclassification of focal segmental glomerulosclerosis in IgA nephropathy.
    Kidney Int. 2024 Mar 28:S0085-2538(24)00235-7. doi: 10.1016/j.kint.2024.
    >> Share

  60. LAFAYETTE R, Barbour S, Israni R, Wei X, et al
    A Phase 2b, randomized, double-blind, placebo-controlled, clinical trial of atacicept for treatment of IgA nephropathy.
    Kidney Int. 2024 Mar 27:S0085-2538(24)00236-9. doi: 10.1016/j.kint.2024.
    >> Share

  61. WANG H, Zuiani J, Coates Ao PT, Xia Y, et al
    Reconstructing the interface between the human intestine and immune system: potential to advance mechanistic studies in IgA nephropathy.
    Kidney Int. 2024;105:423-426.
    >> Share

  62. FLOEGE J, Jayne DRW, Sanders JF, Tesar V, et al
    Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of ANCA-Associated Vasculitis.
    Kidney Int. 2024;105:447-449.
    >> Share


  63. KDIGO 2024 Clinical Practice Guideline for the Management of Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis.
    Kidney Int. 2024;105.
    >> Share

    February 2024
  64. VOINESCU CD, Mozere M, Genovese G, Downie ML, et al
    A Neanderthal haplotype introgressed into the human genome confers protection against membranous nephropathy.
    Kidney Int. 2024 Feb 14:S0085-2538(24)00073-5. doi: 10.1016/j.kint.2024.
    >> Share

  65. TANIGUCHI T, Hiwa R, Morinobu A
    Pitfalls in evaluating the impact of persistent hematuria after induction therapy on kidney prognosis in anti-neutrophil cytoplasmic autoantibody-associated vasculitis.
    Kidney Int. 2024;105:391-392.
    >> Share

  66. WIMBURY D, Muto M, Bhachu JS, Scionti K, et al
    Targeted-release budesonide modifies key pathogenic biomarkers in immunoglobulin A nephropathy: insights from the NEFIGAN trial.
    Kidney Int. 2024;105:381-388.
    >> Share

  67. SEIFERT L, Riecken K, Zahner G, Hambach J, et al
    An antigen-specific chimeric autoantibody receptor NK cell strategy for the elimination of anti-PLA2R1 and anti-THSD7A antibody-secreting cells.
    Kidney Int. 2024 Feb 1:S0085-2538(24)00080-2. doi: 10.1016/j.kint.2024.
    >> Share

    January 2024
  68. WANG H, Shen M, Ma Y, Lan L, et al
    Novel mitophagy inducer alleviates lupus nephritis by reducing myeloid cell activation and autoantigen presentation.
    Kidney Int. 2024 Jan 29:S0085-2538(24)00064-4. doi: 10.1016/j.kint.2023.
    >> Share

  69. ROVIN BH, Ayoub IM, Chan TM, Liu ZH, et al
    Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Management of Lupus Nephritis.
    Kidney Int. 2024;105:31-34.
    >> Share

  70. FLOEGE J
    A new alternative: inhibiting complement activation in patients with IgA nephropathy.
    Kidney Int. 2024;105:28-30.
    >> Share


  71. KDIGO 2024 Clinical Practice Guideline for the management of LUPUS NEPHRITIS.
    Kidney Int. 2024;105.
    >> Share

  72. LUCIENTES-CONTINENTE L, Fernandez-Juarez G, Marquez-Tirado B, Jimenez-Villegas L, et al
    Complement alternative pathway determines disease susceptibility and severity in antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
    Kidney Int. 2024;105:177-188.
    >> Share

  73. DYLEWSKI JF, Haddad G, Blaine J
    Exploiting the neonatal crystallizable fragment receptor to treat kidney disease.
    Kidney Int. 2024;105:54-64.
    >> Share

    December 2023
  74. RIVEDAL M, Mikkelsen H, Marti HP, Liu L, et al
    Glomerular transcriptomics predicts long term outcome and identifies therapeutic strategies for patients with assumed benign IgA nephropathy.
    Kidney Int. 2023 Dec 26:S0085-2538(23)00920-1. doi: 10.1016/j.kint.2023.
    >> Share

  75. KISTLER AD, Salant DJ
    Complement Activation and Effector Pathways in Membranous Nephropathy.
    Kidney Int. 2023 Dec 21:S0085-2538(23)00868-2. doi: 10.1016/j.kint.2023.
    >> Share

  76. ROBSON KJ
    Laminin-521: a novel target for pathogenic autoantibodies in anti-glomerular basement membrane disease.
    Kidney Int. 2023;104:1054-1056.
    >> Share

    November 2023
  77. BECK LH JR
    The latest model has just arrived! A new experimental mouse model of PLA2R1-associated membranous nephropathy.
    Kidney Int. 2023;104:878-880.
    >> Share

    October 2023
  78. ZHANG H, Rizk DV, Perkovic V, Maes B, et al
    Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
    Kidney Int. 2023 Oct 30:S0085-2538(23)00754-8. doi: 10.1016/j.kint.2023.
    >> Share

  79. KIM M, Kim SS, Choi HI, Choi HS, et al
    Cryofibrinogen-associated membranoproliferative glomerulonephritis.
    Kidney Int. 2023;104:860.
    >> Share

  80. TANIGUCHI T, Hiwa R, Morinobu A
    The conclusion that myeloperoxidase inhibition is not protective against anti-neutrophil cytoplasmic autoantibody-associated vasculitis is premature.
    Kidney Int. 2023;104:856.
    >> Share

    September 2023
  81. SETHI S, Beck LH Jr, Glassock RJ, Haas M, et al
    Mayo Clinic consensus report on membranous nephropathy: proposal for a novel classification.
    Kidney Int. 2023 Sep 6:S0085-2538(23)00490-8. doi: 10.1016/j.kint.2023.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016